The evidence is mixed for using infection-fighting antibodies from survivors' blood for Ebola, but without any licensed drugs or vaccines for the deadly disease, some say it's worth a shot.
"This is something that's fairly simple to do," said Dr Peter Piot, director of London's School of Hygiene and Tropical Medicine and the co-discoverer of the Ebola virus.
Using blood of survivors is one of the experimental Ebola treatments under discussion at a two-day meeting that began today in Geneva.
There are about a half dozen medicines and vaccines in development. None has been rigorously tested in humans but early testing of one vaccine began this week in the United States.
Much attention has focused on the untested drug ZMapp, which was given to seven patients, two of whom died. But the limited supply is now exhausted and its developer says it will take months to make even a modest amount.
The group recently issued a paper on how the strategy might be used. It said blood from survivors should be considered experimental and it recommended studies be done during the outbreak.
Some scientists think antibodies in the blood of Ebola survivors could help patients infected with the deadly disease. Antibodies are produced by the body's immune system to fight off harmful things like viruses; they remain in the blood ready to fight off any future infections by the same foreign substance.
"I hope this is the last Ebola outbreak where all we have is isolation, quarantine and supportive care to treat patients," he said.
Experts say blood from survivors could be collected and processed for multiple patients, or a survivor could donate blood to an individual patient. Both methods require screening the blood for diseases like HIV or malaria.
While direct donation would be easier, the levels of Ebola-fighting antibodies produced by a survivor can vary. Ideally, experts said, the amount of antibodies should be measured.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
